Status
Conditions
Treatments
About
The main aim of this descriptive cross-sectional study is to assess the prevalence of chemsex substance use disorder among chemsexers via an online self-questionnaire.
Full description
Chemsex appeared in Europe around 2006 and in France in 2010. It involves the use of psychoactive substances in a sexual context to enhance, initiate, facilitate or prolong sexual intercourse through the psychoactive effects of the molecules consumed. These molecules are essentially synthetic cathinones, GHB/GBL, MDMA, methamphetamines, cocaine and ketamine. These products are often used in combination with erectile dysfunction treatments (side effects of the molecules). This practice is thought to affect almost 20% of MSM.
This use has numerous social, somatic, psychiatric and addictive consequences. Studies have mainly focused on infectious risks, psychiatric complications (e.g. anxiety and depression) or the prevalence of this phenomenon. However, no study has assessed the prevalence of chemsex-related substance use disorders among these users.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Melina FATSEAS; Helen SAVARIEAU
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal